nrd1 Antibody

What is NRD1 and why is it significant in research contexts?

NRD1 (Nardilysin, N-Arginine Dibasic Convertase) is a metalloendopeptidase that plays roles in multiple biological processes. The enzyme is involved in the processing of various bioactive peptides and has been implicated in signaling pathways relevant to development, inflammation, and certain pathological conditions. Research interest in NRD1 stems from its potential roles in neurological disorders, cancer biology, and metabolic regulation. Antibodies against NRD1 are critical tools for investigating its expression patterns, cellular localization, and functional interactions in experimental models .

What types of NRD1 antibodies are available for research applications?

Based on available research materials, multiple types of NRD1 antibodies have been developed for research applications. These include:

• Polyclonal antibodies raised in rabbits against specific regions of the NRD1 protein (e.g., middle region, N-terminal, C-terminal)

• Antibodies targeting specific amino acid sequences within NRD1, such as the sequence GSKMLSVHVV GYGKYELEED GTPSSEDSNS SCEVMQLTYL PTSPLLADCI

• Antibodies generated using recombinant NRD1 protein as immunogen

• Various conjugated forms for different applications (unconjugated, HRP-conjugated, FITC-conjugated, and biotin-conjugated)

The choice of antibody depends on the specific application and experimental requirements.

What are the primary applications of NRD1 antibodies in research settings?

NRD1 antibodies are employed in multiple research applications:

• Western Blotting (WB): For detecting and quantifying NRD1 protein expression in cell or tissue lysates

• Immunohistochemistry (IHC): For visualizing NRD1 distribution in tissue sections

• Immunofluorescence (IF): For studying subcellular localization

• ELISA: For quantitative measurement of NRD1 in various samples

• Immunoprecipitation: For isolation of NRD1 and associated protein complexes

The application determines which antibody characteristics (specificity, sensitivity, format) are most important for successful experiments .

How can I validate the specificity of an NRD1 antibody for my experimental system?

Rigorous validation of NRD1 antibody specificity is essential for reliable research outcomes. A comprehensive validation approach should include:

• Positive and negative controls: Use cell lines or tissues known to express or lack NRD1

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide before application to demonstrate binding specificity

• siRNA/shRNA knockdown: Confirm reduction in signal following NRD1 knockdown

• Correlation with mRNA expression: Compare antibody signal with NRD1 transcript levels

• Cross-reactivity testing: Evaluate potential cross-reactivity with structurally related proteins

• Multiple antibody confirmation: Use antibodies targeting different epitopes of NRD1 to confirm findings

For the commercially available NRD1 antibodies, validation has typically been performed using cell lysates as positive controls, with specificity confirmed through affinity purification techniques .

What are the critical considerations for selecting the appropriate NRD1 antibody epitope for specific research questions?

The selection of antibody epitope is a crucial decision that significantly impacts experimental outcomes:

• Functional domains: Consider whether the epitope is located within a functional domain of NRD1, particularly if studying enzyme activity

• Protein interactions: If studying NRD1 protein interactions, select antibodies targeting regions not involved in those interactions

• Post-translational modifications: Be aware that antibodies may have differential recognition of modified forms of NRD1

• Species conservation: For cross-species applications, evaluate epitope conservation across species

• Accessibility: Consider whether the epitope is accessible in native protein conformation

The antibody described in search result targets the middle region of NRD1 (amino acids sequence GSKMLSVHVV GYGKYELEED GTPSSEDSNS SCEVMQLTYL PTSPLLADCI), which provides specific recognition capabilities with predicted reactivity across multiple species (Human: 100%, Cow: 93%, Horse: 86%, Pig: 93%) .

How do differences in antibody production methods impact experimental outcomes with NRD1 antibodies?

Production methods significantly influence antibody performance:

• Immunization strategy: Antibodies generated against recombinant proteins versus synthetic peptides may recognize different conformational aspects of NRD1

• Purification technique: Affinity-purified antibodies (as in ) typically offer higher specificity than crude serum

• Clonality considerations: Polyclonal antibodies (as described in ) recognize multiple epitopes, which can increase sensitivity but may introduce variability between lots

• Host species selection: The choice of host species (rabbit in ) affects downstream application compatibility

• Validation stringency: Extensively validated antibodies minimize the risk of non-specific binding and false positives

For reproducible results, researchers should maintain detailed records of antibody source, lot number, and validation data for each experiment.

What are the optimal conditions for using NRD1 antibodies in Western blot applications?

For successful Western blot experiments with NRD1 antibodies, consider the following parameters:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors to prevent NRD1 degradation

  • Optimize protein loading (typically 20-50 μg total protein)

• Blocking conditions:

  • 5% non-fat dry milk or BSA in TBST, depending on antibody specifications

  • Block for 1 hour at room temperature

• Antibody dilution:

  • Primary antibody dilution should be optimized (typically 1:500 to 1:2000 for commercial NRD1 antibodies)

  • Incubate overnight at 4°C for optimal results

• Detection system:

  • Choose appropriate secondary antibody compatible with host species (anti-rabbit for antibodies in )

  • Consider signal amplification methods for low-abundance detection

• Controls:

  • Include positive control lysates

  • Consider recombinant NRD1 protein as a standard

When using the antibody described in search result , validation was performed using cell lysate as a positive control, suggesting this approach for experimental validation .

How can I troubleshoot non-specific binding issues with NRD1 antibodies?

Non-specific binding is a common challenge with NRD1 antibodies. Systematic troubleshooting approaches include:

• Increase antibody specificity:

  • Use affinity-purified antibodies (as in )

  • Optimize antibody dilution with titration experiments

  • Consider pre-adsorption with non-target tissues

• Modify blocking conditions:

  • Test alternative blocking agents (milk, BSA, serum, commercial blockers)

  • Increase blocking time or concentration

• Adjust washing protocols:

  • Increase number and duration of washes

  • Use detergents appropriate for your application

• Reduce background signal:

  • For immunohistochemistry/immunofluorescence: autofluorescence reducers or endogenous peroxidase blocking

  • For Western blot: optimize exposure time and increase wash stringency

• Validate with alternative detection methods:

  • Compare results across multiple techniques

  • Correlate with NRD1 mRNA expression data

What are the methodological considerations for NRD1 antibody use across different species?

Cross-species application of NRD1 antibodies requires careful consideration:

• Epitope conservation analysis:

  • The antibody in search result has predicted reactivity with Human (100%), Cow (93%), Horse (86%), and Pig (93%)

  • Sequence alignment of the target epitope across species should be performed

• Validation requirements by species:

  • Each new species application requires independent validation

  • Western blot verification of correct molecular weight in the target species

• Protocol modifications by species:

  • Fixation conditions may need adjustment for different tissues

  • Antigen retrieval methods may require optimization

  • Antibody concentration often needs species-specific titration

• Positive controls selection:

  • Species-matched positive control tissues or cells

  • Recombinant NRD1 from the species of interest

• Negative controls implementation:

  • Pre-immune serum controls

  • Secondary antibody-only controls

How do I quantitatively analyze NRD1 expression data from Western blots?

Quantitative analysis of NRD1 Western blot data requires standardized approaches:

• Image acquisition:

  • Use a digital imaging system with linear dynamic range

  • Avoid saturated signals that compromise quantification

  • Capture multiple exposures to ensure linear range detection

• Normalization strategy:

  • Normalize NRD1 signal to appropriate loading controls (β-actin, GAPDH, total protein)

  • Verify stability of loading control across experimental conditions

• Densitometry analysis:

  • Use software that allows background subtraction (ImageJ, Image Lab, etc.)

  • Define measurement areas consistently across lanes

  • Calculate relative densities compared to controls

• Statistical analysis:

  • Apply appropriate statistical tests based on experimental design

  • Consider biological and technical replicates in analysis

  • Report variability measures (standard deviation, standard error)

• Reporting standards:

  • Present both representative blots and quantification graphs

  • Include molecular weight markers

  • Provide details on antibody dilution and detection methods

How should I reconcile conflicting data when different NRD1 antibodies give inconsistent results?

When faced with inconsistent results from different NRD1 antibodies, follow this systematic approach:

The experience with anti-NMDA receptor antibodies (anti-NR1/NR2 and anti-NR2) described in search result demonstrates the importance of understanding that antibodies targeting different epitopes of the same protein can produce non-overlapping results due to fundamental differences in epitope recognition .

What are best practices for studying NRD1 interactions with other proteins using antibody-based approaches?

To investigate NRD1 protein interactions:

• Co-immunoprecipitation (Co-IP) strategies:

  • Consider epitope accessibility in protein complexes

  • Test multiple antibodies targeting different NRD1 regions

  • Use mild lysis conditions to preserve protein interactions

  • Include appropriate controls (IgG control, reverse Co-IP)

• Proximity ligation assay (PLA) implementation:

  • Requires antibodies from different host species against NRD1 and interaction partners

  • Validate antibody specificity independently

  • Include negative controls (single antibody, non-interacting protein)

• Immunofluorescence co-localization studies:

  • Use high-resolution imaging (confocal, super-resolution)

  • Employ appropriate controls for spectral overlap

  • Quantify co-localization using established algorithms

• Crosslinking approaches:

  • Select reversible crosslinkers for complex preservation

  • Optimize crosslinking conditions to minimize artifacts

  • Use antibodies recognizing epitopes outside crosslinked regions

• Results validation:

  • Confirm interactions with reciprocal experiments

  • Validate with orthogonal methods (yeast two-hybrid, pull-down assays)

  • Map interaction domains through mutational analysis

How can I effectively use NRD1 antibodies in single-cell analysis techniques?

Single-cell applications require special considerations:

• Flow cytometry/CyTOF applications:

  • Test fixation and permeabilization protocols specific for NRD1

  • Optimize antibody concentration through titration

  • Use conjugated antibodies or validated secondary antibodies

  • Include isotype controls and FMO (fluorescence minus one) controls

• Single-cell immunofluorescence:

  • Consider signal amplification methods for low-abundance detection

  • Optimize fixation to preserve antigenicity while maintaining morphology

  • Use spectral unmixing for multi-parameter analysis

• Spatial transcriptomics integration:

  • Correlate protein expression with mRNA localization

  • Optimize protocols for sequential or multiplexed detection

  • Validate antibody compatibility with RNA preservation methods

• Microfluidic applications:

  • Adjust antibody concentrations for reduced volumes

  • Validate specificity in microfluidic environment

  • Develop appropriate washing protocols for microchannels

• Data analysis considerations:

  • Account for technical variability in single-cell measurements

  • Apply appropriate normalization methods

  • Consider dimensionality reduction techniques for multi-parameter data

What methodological approaches should be considered when using NRD1 antibodies in tissue microarrays or high-throughput screening?

For high-throughput applications:

• Standardization requirements:

  • Establish uniform staining protocols across all samples

  • Use automated systems for consistent application

  • Include reference standards on each array/plate

• Validation for high-throughput context:

  • Verify antibody performance in array/plate format

  • Test lot-to-lot consistency

  • Validate signal linearity across expression ranges

• Quantification strategies:

  • Develop reproducible scoring systems

  • Use digital image analysis for objective quantification

  • Apply machine learning approaches for pattern recognition

• Quality control measures:

  • Include positive and negative controls on each array/plate

  • Implement statistical methods to identify outliers

  • Assess intra- and inter-array/plate variability

• Data integration approaches:

  • Correlate NRD1 expression with other molecular markers

  • Integrate with clinical or phenotypic data

  • Apply appropriate statistical methods for multiple comparisons